The phase II FLOWERS trial is ongoing and studying osimertinib with or without savolitinib as first-line therapy in patients with MET-amplified or overexpressed and EGFR-positive locally advanced or metastatic NSCLC [45]. Here, MET is linked to non-small cell lung carcinoma.